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Two asymptomatic, elderly patients with a distant historyof smoking presented with solitary lung masses on
screening chest radiographs ordered by their primary care
physicians. One was an 87-year-old man with a 3.7-cm left
upper lobe mass and the other a 72-year-old woman with a
2.6-cm right upper lobe mass. Both had a significant history
of cardiovascular disease, peripheral vascular disease, and
type II diabetes mellitus. Because of clinical suspicion for a
primary lung malignancy, positron emission tomography/
computed tomography (CT) scans were ordered and demon-
strated increased hypermetabolic activity within the lung
masses, but not within the mediastinum or outside the thorax.
CT-guided biopsies revealed poorly differentiated, nonkera-
tinizing squamous cell carcinoma in both patients. Per stan-
dard guidelines, the patients were referred to a thoracic
surgeon; however, both were deemed high-risk surgical can-
didates.1 Therefore, both patients were referred for definitive
radiotherapy of their stage I lung cancers.
Using CT-based radiotherapy planning, both patients
were treated with stereotactic body radiation therapy (SBRT)
using three doses of 18 Gy delivered within 1 week and at
least 72 hours between each fraction (Figures 1A, B). Per our
standard practice, on each day of treatment, we performed
cone beam CT scans on the treatment machine to ensure
proper positioning before the delivery of each radiotherapy
dose. In these two patients, the cone beam CT scans per-
formed before the first and second radiation doses did not
identify any tumor changes. However, the cone beam CT
scan before the third radiation dose demonstrated a large,
central cavitation within the tumors of both patients (Figures
2A, B). These findings represented a rapid and significant
change from the second treatment cone beam CT that was just
3 days prior. A review of the literature and experienced
practitioners (personal communications) failed to reveal any
similar cases of rapid tumor cavitation during or after SBRT.
The phenomenon of central tumor cavitation in non-
small cell lung cancer has been observed in patients receiving
the antivascular endothelial growth factor antibody, bevaci-
zumab. In two randomized trials, central tumor cavitation
with associated pulmonary hemorrhage was observed in pa-
tients receiving bevacizumab, carboplatin, and paclitaxel, but
not in those receiving just carboplatin and paclitaxel.2,3 A
subsequent pooled matched analysis from these studies found
that pretreatment tumor cavitation was the only significant
factor predictive of pulmonary hemorrhage in the setting of
bevacizumab.4 This pretreatment cavitation could actually
reflect already compromised vasculature. We speculate that
SBRT-mediated damage acted similar to the antivascular
effects of bevacizumab.5 Both patients presented here had
significant atherosclerotic disease in the setting of type II
diabetes mellitus. SBRT may have been the tipping point for
occluding the already compromised vasculature that lead to
nutrient depletion and subsequent rapid central necrosis and
cavitation. This is merely a hypothesis-generating observa-
tion; however, it should be followed carefully because central
cavitation has been a harbinger for severe and lethal toxicity
in patients with non-small cell lung cancer treated with
systemic antivascular therapy.2
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FIGURE 1. Radiation isodose distribution in coronal, axial, and sagittal planes for patient 1 (A, February 2, 2009) and patient
2 (B, March 23, 2009). Volume of tissue receiving 50% (2700 cGy, light blue), 95% (5130 cGy, dark blue), 100% (5400 cGy,
red), 105% (5670 cGy, orange), 110% (5940, yellow), and 120% (6480 cGy, white) of total radiation dose are displayed.
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FIGURE 2. Cone beam computed tomography (CT) scans before the third and final dose of radiation in coronal, axial, and
sagittal planes for patient 1 (A, February 9, 2009) and patient 2 (B, March 30, 2009). Both patients demonstrated rapid and
significant central cavitation of their tumors when compared with the second treatment cone beam CT that was just 3 days
prior.
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